University of York
The York Biomedical Research Institute is a new cross-departmental initiative set up to expand and consolidate York’s international expertise in biomedical research within the University. Our research, under the Immunology, Haematology and Infection theme, ranges from fundamental studies on the pathogenesis of infectious and non-infectious disease through to first-in-man clinical research.
The Centre for Health Economics is a leading international Centre of Excellence in health economics; home to 50 economists and regularly undertakes analyses for and advises organizations such as NICE, the Bill and Melinda Gates Foundation and the WHO.
Nidhi Dey is post-doctoral researcher in the Kaye, Walrad and Lagos laboratory at the York Biomedical Research Institute. She did her undergraduate degree in biotechnology in 2005 followed by Masters in Biotechnology in 2007 funded by the Department of Biotechnology, India. After working as a research assistant at IIT, Delhi she began a PhD in developmental biology at Indian Institute of Science Education and Research (IISER), Mohali in 2009 looking at hematopoeitic stem cells and its niche in Drosophila. She is currently working on Tegumentary Leishmaniasis using in-situ hybridisations to locate parasites and to identify molecular signatures of host response to the disease.
Liz Greensted has worked as a senior administrator in the field of higher education for over 20 years, in a variety of research environments. Liz joined LeishPathNet in March 2017. She is responsible for project managing the activities of both this project and LeishChallenge (https://leishchallenge.org)
Paul Kaye is Professor of Immunology at the University of York. He trained in zoology (BSc) and immunology (PhD) and has worked for over 30 years on the immunology and immunopathology of the neglected tropical disease leishmaniasis. He is internationally recognized for his research on macrophages and dendritic cells, contributing to a fundamental understanding of their biology in health and disease, and for his work on lymphoid tissue remodelling and granulomatous inflammation during chronic infection. Paul is a Wellcome Senior Investigator and an elected Fellow of the UK Academy of Medical Sciences. He was awarded FRCPath by publication in 2004 and has published over 150 articles and reviews, with numerous articles in leading international journals (e.g. Nature Medicine, Immunity, J. Clin. Invest., PNAS). Paul’s research tackles leishmaniasis from a holistic viewpoint, rooted in the immunology of the host-parasite interaction, but employing tools and approaches taken from many disciplines, including mathematics, ecology, vector biology and neuroscience. He has extensive links with leishmaniasis-endemic countries and is currently leading a Phase II therapeutic vaccine trial in Sudan and developing a digital pathology platform to facilitate a greater understanding of disease pathogenesis through data sharing and collaboration across geographic borders.
Dimitris Lagos is a Senior Lecturer in Immunology at the University of York, leading the RNA Immunobiology Group. Following his degree in Chemical Engineering, Dimitris’ PhD work on monoclonal antibody engineering resulted in one of the first examples of a fully synthetic, in vitro evolved scFV (Nature Biotechnology 2003). After his PhD, Dimitris moved to UCL to study host-pathogen interactions. His work on gene regulatory networks during infectious and inflammatory diseases has resulted in publications in leading peer reviewed journals (Nature Genetics, Nature Cell Biology, PNAS, Genes & Development, Cell Host & Microbe). In 2011, he established his group in York and in 2014 received a Medical Research Council New Investigator Research Grant. In the last decade Dimitris’ work has focused on the role of non-coding RNAs (microRNAs and lncRNAs) in immunity. He collaborates extensively with clinician and basic scientists and his work extends from single molecule to whole organism, integrating a range of biochemical, immunological, computational, and molecular cell biology experimental medicine approaches.
Dr Layton is a Consultant Dermatologist at Harrogate and District NHS Foundation Trust, Co-clinical Director for the National Institute for Health Research Yorkshire and Humber Clinical Research Network and Associate Medical Director for Research and Development within her trust. She holds an Honorary Senior Clinical Lecturer Post at Hull York Medical School and is a clinical affiliate for the Centre of Immunology and Infection at the School of Biology at York University.
Over the years she has acted as Chief or Principle Investigator for many clinical trials (Phase I-IV). Studies have examined the efficacy of treatment in a number of common inflammatory dermatoses including acne as well as novel products and devices aligned to dermato-oncology and wound care. She has collaborated on basic science research projects with the Centre of Immunology and Infection (CII) at the School of Biology at York University and Departments of Microbiology at Leeds and Bradford University.
Dr Layton’s primary research interest lies within the field of androgen related skin disorders particularly acne vulgaris. She currently leads a tertiary referral service for acne and has developed a comprehensive ethically approved acne database over the last 15 years. She is co-applicant on a National Institutes for Health grant examining core outcome measures for use in clinical trials of acne. Through this an international network has been developed ACORN (Acne Core Outcome Research Network) and this is informing the development of standardised outcome measures for use in clinical trials.
She is collaborating with an SME who have secured a Horizon 2020 grant to support digital imaging for skin disease. She represents the UK as a member of European and International Global Alliance Acne Panels and was recently nominated as a member of the European Dermatology Forum. She has published widely and acted as clinical lead for Evidence Based Guidelines and Cochrane Systematic Reviews.
Paul is a Senior Research Fellow for the Team for Economic Evaluation and Health Technology Assessment (TEEHTA) at the Centre for Health Economics (CHE), University of York. He is the Theme Lead in Global Health Economic Evaluation at CHE. Paul’s research interests revolve around the development of methods and applied economic evaluation to inform resource allocation decisions within health care sectors of low- and middle-income countries, particularly in sub-Saharan Africa. The underlying aim of his work is to ensure that resources committed to health care are spent in ways likely to lead to greatest improvements in population health and wellbeing, recognising the complexities of real world healthcare systems. He has published over 25 articles, including in leading international health journals (e.g. Nature, Lancet Global Health, Journal of Infectious Diseases) and has regularly been invited to present at and participate in meetings convened by international organizations (e.g. World Bank, WHO, PEPFAR, Bill and Melinda Gates Foundation).
Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he is Director of the Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions, a seven-year programme, run collaboratively with the University of Sheffield and funded by the UK Department of Health.
Mark has worked in the field of economic evaluation and health technology assessment for 30 years. He has researched in a range of clinical areas including heart disease, cancer, diagnostics, and public health. He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty, heterogeneity and generalisability. He has over 250 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2015 with Drummond, Claxton, Torrance and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton).
Mark is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE’s Diagnostics Advisory Committee. He chaired NICE’s 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance. He has also advised health systems internationally on HTA methods including those in France, Ireland, Japan, Singapore, Germany, Portugal, and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme, the UK NIHR /Medical Research Council’s Methodology Research Panel, and the UK Department of Health’s Policy Research Programme’s Commissioning Panel. He served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2011-12).
Pegine Walrad is a Research Lecturer at the University of York. She trained in zoology (BSc), developmental genetics (PhD) and veterinary medicine and has worked for over 10 years characterizing the molecular biology of kinetoplastid parasites. Pegine is a Medical Research Council New Investigator and is internationally recognised as a leader in parasite gene regulatory mechanisms. Pegine’s research examines molecular pathways of the Leishmania parasite lifecycle progression to human-infectious forms employing a range of multidisciplinary tools and approaches including biophysics, informatics, genetics, mathematics, and structural and molecular biochemistry. She has established vital research links with international collaborators in leishmaniasis-endemic countries with support from the Royal Society, MRC, CONFAP and Science without Borders and has led invited courses on parasite genetics both at home and abroad.
- A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
- Conserved asymmetry underpins homodimerization of Dicer-associated double-stranded RNA-binding proteins
- Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
- Developmental differentiation in Leishmania lifecycle progression: post-transcriptional control conducts the orchestra.
- Identifying What to Measure in Acne Clinical Trials: First Steps towards Development of a Core Outcome Set.
- Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients
- Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients
- Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys.
- M2 Polarization of Monocytes-Macrophages Is a Hallmark of Indian Post Kala-Azar Dermal Leishmaniasis
- MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
- Skin parasite landscape determines host infectiousness in visceral leishmaniasis.
- Tegumentary leishmaniasis and coinfections other than HIV
- The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.
- VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy